歌礼制药-B(01672.HK) 公布,ASC30口服片治疗肥胖症患者美国Ia期单剂量递增研究中整体安全性和耐受性良好,意味ASC30口服片有望成为治疗肥胖症的同类最佳小分子口服GLP-1R激动剂。
ASC30是歌礼自主研发的小分子GLP-1R偏向激动剂,是首款也是唯一一款既可每月一次皮下注射也可每日一次口服用于治疗肥胖症的小分子GLP-1R激动剂。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.